https://www.benzinga.com/news/23/10/35097954/veracyte-stock-is-volatile-after-hours-heres-why
Veracyte Stock Is Volatile After-Hours - Here's Why - Veracyte (NASDAQ:VCYT) - Benzinga
Oct 4, 2023 - Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value...
after hours
https://www.plus500.com/en-ae/instruments/vcyt
Veracyte (VCYT) CFDs
Track the latest Veracyte stock price at 41.28 with a 7.82% daily change (indicative prices). Buy/sell Veracyte (VCYT) share CFDs.
veracytecfds
https://www.barchart.com/stocks/quotes/VCYT/opinion-legacy/7-Day-Directional-Indicator/strategy-charts
VCYT Barchart Opinion for Veracyte Stock - Barchart.com
Barchart is the leading provider of real-time stock and commodities data. Keep tabs on your portfolio with screeners, customizable charts and analysis.
barchartopinionveracytestock
https://www.home.saxo/cs-cz/markets/stocks/vcyt-xnas
Veracyte Inc. akcie | Saxo Bank
Veracyte Inc is a genomic diagnostics company.
veracyteincakciesaxobank
https://finviz.com/quote?t=VCYT
VCYT - Veracyte Inc Stock Price and Quote
VCYT - Veracyte Inc - Stock screener for investors and traders, financial visualizations.
stock priceveracyteincquote
https://www.benzinga.com/news/earnings/23/02/30993103/a-preview-of-veracytes-earnings
A Preview Of Veracyte's Earnings - Veracyte (NASDAQ:VCYT) - Benzinga
a previewveracyteearningsnasdaqbenzinga
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/are-veracyte-incs-nasdaqvcyt-fundamentals-good-enough-to-war
Are Veracyte, Inc.'s (NASDAQ:VCYT) Fundamentals Good Enough to Warrant Buying Given The Stock's...
With its stock down 23% over the past three months, it is easy to disregard Veracyte (NASDAQ:VCYT). But if you pay...
https://www.biospace.com/press-releases/veracyte-to-release-first-quarter-2025-financial-results-on-may-7-2025
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025 - BioSpace
2025 financial resultsfirst quarter
https://www.biospace.com/veracyte-to-release-first-quarter-2023-financial-results-on-may-4-2023
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023 - BioSpace
Apr 14, 2023 - Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May...
first quarter2023 financial
https://www.businesswire.com/news/home/20260414666656/en/Veracyte-to-Release-First-Quarter-2026-Financial-Results-on-May-5-2026
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after ...
first quarter 2026financial resultsveracyterelease
https://www.prnewswire.com/news-releases/veracyte-to-host-conference-call-and-webcast-to-discuss-fourth-quarter-and-full-year-2015-financial-results-on-march-10-300225565.html
Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2015 Financial...
/PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2015 financial results after close of...
https://www.veracyte.com/
Veracyte – Your Ally in Cancer Care
Jun 25, 2026 - Veracyte serves as an ally in the race against cancer, providing clinicians and patients with molecular tests that reveal key insights into tumor biology.
veracyteallycancercare
https://www.biospace.com/veracyte-announces-third-quarter-2021-financial-results
Veracyte Announces Third Quarter 2021 Financial Results - BioSpace
Nov 10, 2021 - Veracyte, Inc.Veracyte, Inc. announced financial results for the third quarter ended September 30, 2021.
third quarter2021 financialveracyteannouncesresults
https://www.news-medical.net/news/20181008/Veracyte-to-present-data-demonstrating-potential-of-Envisia-Genomic-Classifier-to-improve-ILD-diagnosis.aspx
Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD...
Oct 8, 2018 - Veracyte, Inc. announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial...
https://www.egyptindependent.com/veracyte-lung-cancer-test-could-help-avoid-some-risky-biopsies/
Veracyte lung cancer test could help avoid some risky biopsies - Egypt Independent
May 18, 2015 - A new diagnostic test from Veracyte Inc could help many people avoid risky and costly invasive lung biopsies at a time when millions of American smokers are...
lung cancer
https://www.benzinga.com/quote/VCYT/guidance
Veracyte Stock Guidance | NASDAQ:VCYT | Benzinga
Access expert guidance on Veracyte stock with Benzinga. Stay informed on market forecasts, trends, and investment strategies for VCYT.
veracytestockguidancenasdaqbenzinga
https://www.benzinga.com/m-a/21/06/21368666/veracyte-strengthens-cancer-diagnostics-portfolio-with-haliodx-acquisition
Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition - Veracyte (NASDAQ:VCYT)...
cancer diagnosticsveracyteportfolioacquisitionnasdaq
https://www.home.saxo/fr-ch/markets/stocks/vcyt-xnas
Veracyte Inc. action | Saxo Bank Suisse
Veracyte Inc is a genomic diagnostics company.
saxo bankveracyteincactionsuisse
https://www.youtube.com/user/GenomeDx
Decipher by Veracyte - YouTube
Veracyte offers the Decipher genomic tests for urologic cancers.
decipherveracyteyoutube
https://www.barchart.com/stocks/quotes/VCYT/analyst-ratings
VCYT Analyst Ratings for Veracyte Stock - Barchart.com
Analyst Ratings for Veracyte Inc (VCYT) provide recommendations made by outside industry experts.
analyst ratingsveracytestockbarchart
https://www.biospace.com/veracyte-announces-third-quarter-2020-financial-results
Veracyte Announces Third Quarter 2020 Financial Results - BioSpace
Nov 3, 2020 - Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2020 and provided an update on recent business...
third quarter2020 financialveracyteannouncesresults